Outcomes and pathologic response of primary lung cancer treated with tyrosine kinase inhibitor/immune checkpoint inhibitor before salvage surgery-Reference-Cited by-同舟云学术

Outcomes and pathologic response of primary lung cancer treated with tyrosine kinase inhibitor/immune checkpoint inhibitor before salvage surgery

Published:2024-03-14 Issue: Volume: Page:
ISSN:0941-1291
Container-title:Surgery Today
language:en
Short-container-title:Surg Today

Author:

Takenaka Masaru^ORCID,Tanaka Fumihiro,Kajiyama Kenta,Manabe Takehiko,Yoshimatsu Katsuma,Mori Masataka,Kanayama Masatoshi,Taira Akihiro,Kuwata Taiji,Nawata Aya,Kuroda Koji

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00595-024-02811-3.pdf

Reference30 articles.

1. Bauman JE, Mulligan MS, Martins RG, Kurland BF, Eaton KD, Wood DE. Salvage lung resection after definitive radiation(>59Gy) for non-small cell lung cancer: surgical and oncologic outcomes. Ann Thorac Surg. 2008;86:1632–8.

2. Kuzmik GA, Detterbeck FC, Decker RH, Boffa DJ, Wang Z, Oliva IB, et al. Pulmonary resections following prior definitive chemoradiation therapy are associated with acceptable survival. Eur J Cardiothorac Surg. 2013;44:e66-70.

3. Yang CF, Meyerhoff RR, Stephens SJ, Singhapricha T, Toomey CB, Anderson KL, et al. Long-term outcomes of lobectomy for non-small cell lung cancer after definitive radiation treatment. Ann Thorac Surg. 2015;99:1914–20.

4. Yang CJ, Gu L, Shah SA, Yerokun BA, D’Amico TA, Hartwig MG, et al. Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: a national analysis. Lung Cancer. 2018;115:75–83.

5. Jia J, Guo B, Yang Z, Liu Y, Ga L, Xing G, et al. Outcomes of local thoracic surgery in patients with stage IV non-small-cell lung cancer: a SEER-based analysis. Eur J Cancer. 2021;144:326–40.